Skin Manifestations in Pediatric Patients Treated With a TNF-Alpha Inhibitor for Inflammatory Bowel Disease: A Retrospective Study
| Autor: | Maria‐Laura Cossio, Afshin Hatami, Prevost Jantchou, Colette Deslandres, Annie Genois, Catherine McCuaig |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Skin manifestations
medicine.medical_specialty Necrosis Tnf alpha antagonists business.industry Alpha (ethology) Retrospective cohort study Dermatology medicine.disease Gastroenterology Inflammatory bowel disease 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Psoriasis Internal medicine medicine 030211 gastroenterology & hepatology Surgery Tumor necrosis factor alpha medicine.symptom business |
| Zdroj: | Journal of Cutaneous Medicine and Surgery. 24:333-339 |
| ISSN: | 1615-7109 1203-4754 |
| DOI: | 10.1177/1203475420917387 |
| Popis: | Background Tumor necrosis factor (TNF) alpha inhibitors (anti-TNF) are effective in the treatment of inflammatory bowel disease (IBD) as well as psoriasis. Their increasing use has raised the identification of cutaneous side effects (CSEs). Evidence in children is limited. Objectives The objective of this study is to describe CSEs of anti-TNF treatment in a pediatric population with IBD. Methods This is a retrospective single-center study of children with IBD under anti-TNF treatment between 2013 and 2016. A total of 40 patients with CSEs related to anti-TNF were referred to our pediatric dermatology clinic. A control group was randomly selected from patients receiving anti-TNF for IBD, who were referred to the dermatology clinic for other conditions unrelated to anti-TNF. Results Of 343 patients with IBD, 40 (11.3%) presented CSEs potentially related to the treatment. No differences in sex, age, and underlying disease were found between those with and without CSEs. The most frequent CSEs were psoriasiform eruptions (41%) which were more exudative than usual, located especially in skin folds and on the scalp; skin infections (20%); and eczematous eruptions (10%). Only 5% of patients changed or discontinued the current anti-TNF because of CSEs. Conclusion This is one of the largest pediatric cohorts of IBD patients with CSEs. Psoriasiform eruptions were the most common CSEs, with predilection for skin folds and scalp, and frequent superimposed bacterial infection. Topical and/or systemic antibiotics were required in addition to topical corticosteroids in 25% of patients. The rate of discontinuation of anti-TNF therapy due to CSEs was low. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|